Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin

Inclusion Criteria: 1. ≥ 18 years old 2. Ability to provide Informed Consent 3. Qualification by nephrologist to kidney biopsy in accordance to current standards 4. Initial haemoglobin concentration \> 8g/dl and PLT count \>100 x103/μL 5. Normal range of APTT and INR 6. Blood pressure control defined as SBP\<160 mmHg 7. Permitted antiplatelet/antithrombotic drugs: acetylsalicylic acid and heparin 8. No inflammation at the point of biopsy needle insertion Exclusion Criteria: 1. Initial sodium concentration \<130mmol/l 2. Pregnancy and breastfeeding 3. Anaphylactic shock after desmopressin administration (medical history) 4. Necessity of administration other anti-platelet / anti thrombotic drugs other than acetylsalicylic acid, non-fractionated heparin or low molecular weight heparin 5. Decompensated Heart failure 6. Von Willebrand disease (VWD) type II B 7. As per Investigator opinion a medical situation which may lead to increased intracranial pressure (ICP) 8. Hydronephrosis of the biopsied kidney 9. Usage of any prohibited drug before screening : * ASA in dosage \> 75mg per day * Vitamin K antagonist (VKA) * Direct oral anticoagulants (DOAC) * Low-molecular-weight heparin (LMWH) * Unfractionated heparin (UFH) * Except situation when dosage of listed above drugs will be adjusted in accordance to protocol